|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2005-12-2
|
|
pubmed:abstractText |
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon beta-1a in subjects with PPMS. The key questions were whether S100B levels were associated with either disability or MRI findings in primary progressive MS and whether Interferon beta-1a has an effect on their S100B levels. Serial serum S100B levels were measured using an ELISA method. The results demonstrated that serum S100B is not related to either disease progression or MRI findings in subjects with primary progressive MS given Interferon beta-1a. Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-10371521,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-10462039,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-10482262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-11390274,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-12076997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-12525716,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-2581917,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-3110648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-7354371,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-8469318,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-8602746,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-8848188,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-9007089,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-9007090,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-9236913,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-9757414,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-9820296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15482599-9820297
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1477-5751
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4
|
|
pubmed:dateRevised |
2011-11-3
|
|
pubmed:meshHeading |
pubmed-meshheading:15482599-Adult,
pubmed-meshheading:15482599-Case-Control Studies,
pubmed-meshheading:15482599-Female,
pubmed-meshheading:15482599-Humans,
pubmed-meshheading:15482599-Interferon-beta,
pubmed-meshheading:15482599-Magnetic Resonance Imaging,
pubmed-meshheading:15482599-Male,
pubmed-meshheading:15482599-Multiple Sclerosis, Chronic Progressive,
pubmed-meshheading:15482599-Nerve Growth Factors,
pubmed-meshheading:15482599-S100 Proteins
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
|
|
pubmed:affiliation |
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK. e.lim@ion.ucl.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
